An Oral GnRH Antagonist to Treat Mild Autonomous Cortisol Excess (MACE) Due to Adrenal Adenomas in Postmenopausal Women
Condition(s):Mild Autonomous Cortisol ExcessLast Updated:July 27, 2023Recruiting
Include Studies Not Open or Pending
Condition(s):Mild Autonomous Cortisol ExcessLast Updated:July 27, 2023Recruiting
Condition(s):Cardiac EventsLast Updated:February 14, 2024Recruiting
Condition(s):Chest PainLast Updated:January 9, 2024Recruiting
Condition(s):Diabetes Mellitus, Type 2; Myocardial InfarctionLast Updated:September 5, 2023Recruiting
Condition(s):Anticoagulant Drugs; Antiplatelet Drug; Peripheral Arterial DiseaseLast Updated:May 10, 2023Recruiting
Condition(s):ObesityLast Updated:March 12, 2024Recruiting
Condition(s):Cardiomyopathy; Arrhythmia-induced Cardiomyopathy (AiCM)Last Updated:February 13, 2024Recruiting
Condition(s):Atrial FibrillationLast Updated:January 22, 2024Not yet recruiting
Condition(s):Myocardial Infarction, AcuteLast Updated:September 15, 2023Recruiting
Condition(s):ConstipationLast Updated:November 14, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.